- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19, Christoph D. Spinner, MD, JAMA,2020
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes, Shengli Xia, BS ,JAMA,2020
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 – Goldman JD, et al. N Engl J Med, 2020.
- Remdesivir for the Treatment of Covid-19 — Preliminary Report – Beigel JH, et al. N Engl J Med, 2020.
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial – Hung I.F-N., et al. Lancet, 2020.
- Covid-19 — The Search for Effective Therapy – Baden LR, et al. N Engl J Med, 2020. 5/7
- Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2 – Chiotos K, et al. J Pediatr Infect Dis Soc, 2020
- Compassionate Use of Remdesivir for Patients with Severe Covid-19 – Grein J, et al. N Engl J Med, 2020
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 – Cao B, et al. N Engl J Med, 2020
- Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial – Li L, et al. JAMA, 2020.
- Treatment of COVID-19 Patients With Convalescent Plasma – Salazar E, et al. Am J Pathol, 2020.
- Convalescent plasma transfusion for the treatment of COVID-19: Systematic review – Rajendran K, et al. J Med Virol, 2020.
- Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients – Zeng Q-L, et al. J Infect Dis, 2020.
- Treatment With Convalescent Plasma for COVID-19 Patients in Wuhan, China – Ye M, et al. J Med Virol, 2020.
- Effectiveness of convalescent plasma therapy in severe COVID-19 patients – Duan K, et al. PNAS, 2020.
- Convalescent Plasma to Treat COVID-19: Possibilities and Challenges Roback JD & Guarner J. JAMA, 2020..
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma– Shen C, et al. JAMA, 2020
- Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis – Mehra m, et al. Lancet, 2020.
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 – Boulware DR, et al. N Engl J Med, 2020 .
- Caution against corticosteroid-based COVID-19 treatment – Tang C, et al. Lancet, 2020.
- Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial – Tang W, et al. BMJ, 2020.
- Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data – Mahévas M, et al. BMJ, 2020.
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State – Rosenberg ES, et al. JAMA, 2020.
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 – Geleris J, et al. N Engl J Med, 2020.
- Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know – Yazdany J&Kim AHJ, Ann Intern Med, 2020
- Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury – Russel CD, et al. Lancet, 2020